Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation
Inagaki, J.; Ogawa, M.; Horikoshi, N.; Ezaki, K.; Inoue, K.; Aiba, K.; Komyo, M.; Miyamoto, H.; Ikeda, K.; Kubo, H.
Gan no Rinsho. Japan Journal of Cancer Clinics 29(10): 1291-1295
1983
ISSN/ISBN: 0021-4949 PMID: 6685195 Document Number: 211327
Twenty-seven patients with advanced ovarian cancer were treated with CAPF therapy consisting of CPA, ADM, CPDD, and 5-FU. Twenty patients were evaluable for responses. Fourteen patients (70%) had a complete (6 patients) or partial response (8 patients). The median survival time for responders was 12.0+ months and 4.0 for non-responders. Leukopenia and renal toxicity were dose limiting factors. A second-look operation was performed in 12 patients who had favorable results from CAPF. A combined modality with CAPF and second-look operation seemed to be promising.